Fractyl Health, a groundbreaking healthcare company based in Boston, MA, is revolutionizing the way we manage diabetes. They have developed innovative solutions that go beyond traditional insulin shots, offering new hope for millions of people living with diabetes.
One of Fractyl Health's most game-changing solutions is their Revita™ System. This minimally invasive procedure is designed to treat type 2 diabetes by targeting the root cause of the disease - the lining of the duodenum, a part of the small intestine. By using radiofrequency energy to ablate the duodenal mucosa, the Revita™ System aims to restore the body's natural metabolic function, potentially reducing or even eliminating the need for insulin injections.
Not only does the Revita™ System offer a non-surgical alternative to traditional treatments, but it also has the potential to provide long-lasting results. Fractyl Health's clinical trials have shown promising outcomes, with participants experiencing significant improvements in blood sugar control and insulin sensitivity.
Another exciting development from Fractyl Health is their Intestinal Neural Signaling (INS) Therapy. This therapy focuses on the communication between the gut and the brain, which plays a crucial role in regulating blood sugar levels. By modulating these neural signals, Fractyl Health aims to improve glucose control in individuals with type 2 diabetes.
Fractyl Health's innovative approach to diabetes management has garnered attention and support from the medical community. They have received funding from reputable investors, including GV (formerly Google Ventures) and the JDRF T1D Fund, further validating the potential of their solutions.
With their groundbreaking technologies and commitment to advancing diabetes care, Fractyl Health is poised to make a significant impact on the lives of individuals with diabetes. Their game-changing solutions offer hope for a future where insulin shots may no longer be the primary treatment for managing this chronic condition.
- Fractyl Health. (n.d.). Retrieved from https://www.fractyl.com/
- Fractyl Health Announces Positive Results From Revita-1 Clinical Trial in Type 2 Diabetes. (2021, March 26). Retrieved from https://www.fractyl.com/fractyl-health-announces-positive-results-from-revita-1-clinical-trial-in-type-2-diabetes/
- Fractyl Health. (2021, January 5). Retrieved from https://www.jdrf.org/t1d-resources/about/fractyl-health/
How to Contact Us:
Call us: +1 781-902-8800
Address: 17 Hartwell Ave, Lexington, MA 02421, USA